Cellectis S.A. (CLLS) News

Cellectis S.A. (CLLS): $10.77

-0.46 (-4.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CLLS News Items

CLLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLLS News Highlights

  • For CLLS, its 30 day story count is now at 3.
  • Over the past 8 days, the trend for CLLS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • GENE and SITC are the most mentioned tickers in articles about CLLS.

Latest CLLS News From Around the Web

Below are the latest news stories about Cellectis SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, in collaboration with Professor Toni Cathomen, scientific director at the Center for Chronic Immunodeficiency Medical Center at the University of Freiburg, Germany, will present two oral presentations at the Eur

Yahoo | October 19, 2021

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), to be held in Washing

Yahoo | October 12, 2021

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights09/30/202145,465,31051,066,417 About CellectisCellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-s

Yahoo | October 11, 2021

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Chris Markoch on InvestorPlace | September 15, 2021

TCR-based Therapies Market Skyrocketing $4 Bn by 2028| Autolus, bluebird bio, CARsgen Therapeutics, Celgene, Cell Medica, Cellectis, Cellular Biomedicine Group, Immunocore, Innovative Cellular Therapeutics, Kite Pharma, Lion TCR, ZIOPHARM Oncology

TCR-based Therapies Market is projected to reach at $4 Bn at a CAGR +13% by the time lapse of 2021-28. TCR-based Therapies involves treating cancer with activated T lymphocytes from the body. Both strategies attach new receptors to the cells'' surfaces,

OpenPR | September 10, 2021

Cellectis Announces Participation in Five Investor Conferences

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.

Intrado Digital Media | August 26, 2021

T-Cell Immunotherapy Market Set for Rapid Growth and Trend by 2021-2027 | Cellectis, Takara Bio

This informative T-Cell Immunotherapy market report covers small bunch of information for a scope of period including from 2021 to 2027. This figure ends up being exceptionally gainful for the forthcoming business sector business people. This information in a factual

OpenPR | August 18, 2021

Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript

At this time, I'll now turn the conference over to Eric Dutang, Chief Financial Officer. Thank you, and welcome everyone to Cellectis' second quarter 2021 corporate update and financial results conference call. Joining me on the call today with prepared remarks is Dr. Andre Choulika, our Chief Executive Officer; Dr. Carrie Brownstein, our Chief Medical Officer; and Steve Doares, our Senior Vice President of U.S. Manufacturing will be joining for the Q&A.

Yahoo | August 6, 2021

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients.

Intrado Digital Media | August 5, 2021

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic diseases, announced that it will report its financial results for the second quarter and first six-month period ending June 30, 2021, on Thursday, August 5, 2021, after the close of the US market. The announcem

Yahoo | July 29, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6057 seconds.